Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
An open-label proof of concept study regarding the use of Secukinumab (Cosentyx) in patients with necrobiosis lipoidica diabeticorum (NLD)
- ClinicalTrials.gov Identifier: NCT03791060
- Protocol Number: 2018P000634
- Principal Investigator: Alexandra Kimball
- Principal Investigator: Martina Porter
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required